#LNP3693
LightNews LightNews
newsen.bsky.social
Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025#India#Mumbai#Lupin_Limited#ESMO_Congress#LNP3693
Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025
Lupin Limited is set to present critical Phase 1 data on LNP3693, a STING agonist, at the ESMO Congress 2025, highlighting potential advances in cancer treatment.
third-news.com
October 13, 2025 at 9:44 AM
newsen.bsky.social
Lupin to Showcase Phase 1 Findings of LNP3693 at ESMO 2025 Congress in Berlin#India#Mumbai#Lupin#LNP3693#ESMO2025
Lupin to Showcase Phase 1 Findings of LNP3693 at ESMO 2025 Congress in Berlin
Lupin Limited is set to present results from its Phase 1a trial of LNP3693, a STING agonist, at ESMO 2025, highlighting safety and efficacy for solid tumors.
third-news.com
October 13, 2025 at 9:44 AM
newsen.bsky.social
Lupin to Present Phase I Data on LNP3693 at ESMO 2025 Congress#India#Mumbai#Lupin_Limited#ESMO_2025#LNP3693
Lupin to Present Phase I Data on LNP3693 at ESMO 2025 Congress
Lupin Limited will showcase critical Phase I trial data for LNP3693, a STING agonist, at the ESMO 2025 Congress in Berlin, highlighting its potential in oncology.
third-news.com
October 13, 2025 at 9:43 AM
newsen.bsky.social
Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin#India#Mumbai#Lupin_Limited#ESMO_Congress#LNP3693
Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin
Lupin Limited is set to present data from its Phase 1 trial of LNP3693, a STING agonist, at the ESMO 2025 Congress in Berlin, showcasing its potential in treating advanced solid tumors.
third-news.com
October 13, 2025 at 9:43 AM
newsen.bsky.social
Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025#India#Mumbai#Lupin_Limited#ESMO_Congress#LNP3693
Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025
Lupin Limited announces the presentation of Phase-1 findings for LNP3693 at the ESMO Congress 2025, highlighting its potential in cancer treatment.
third-news.com
October 13, 2025 at 9:42 AM
l2plabs.bsky.social
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress...
dlvr.it
October 13, 2025 at 9:31 AM
l2plabs.bsky.social
Lupin kündigt Präsentation von Phase-1-Daten zu LNP3693 (STING-Agonist) auf dem ESMO-Kongress 2025 an
MUMBAI, Indien, und NAPLES, Florida, und BERLIN, 13. Oktober 2025 /PRNewswire/ -- Der globale Pharmakonzern Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) wird vom 17. bis 21. Oktober 2025 auf dem ESMO-Kongress in Berlin Daten aus der klinischen...
dlvr.it
October 13, 2025 at 9:31 AM
l2plabs.bsky.social
Lupin anuncia la presentación de datos de la fase 1 de LNP3693 (agonista de STING) en el Congreso ESMO 2025
MUMBAI, India y NAPOLES, Fla. y BERLIN, 13 de octubre de 2025 /PRNewswire/ -- La importante farmacéutica mundial Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) presentará los datos de su ensayo clínico de fase 1a que evalúa LNP3693, un agonista de...
dlvr.it
October 13, 2025 at 9:31 AM
l2plabs.bsky.social
Lupin annonce la présentation de données de phase I sur le LNP3693 (agoniste de STING) au congrès ESMO 2025
MUMBAI, Inde, NAPLES, Floride, États-Unis et BERLIN, Allemagne, 13 octobre 2025 /PRNewswire/ -- Lupin Limited (Lupin) (BSE : 500257) (NSE : LUPIN) (REUTERS : LUPIN.BO) (BLOOMBERG : LPCIN) présentera les données de son essai clinique de phase Ia évaluant le LNP3693, un agoniste de STING,...
dlvr.it
October 13, 2025 at 9:31 AM
l2plabs.bsky.social
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress...
dlvr.it
October 13, 2025 at 9:31 AM